Literature DB >> 27202291

Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.

V P Retèl1, L M G Steuten2, J C Mewes2, W H van Harten2.   

Abstract

Entities:  

Year:  2014        PMID： 27202291     DOI： 10.1016/j.jval.2014.08.2307

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  4 in total

Review 1.  Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.

Authors:  Darío Rubio-Rodríguez; Silvia De Diego Blanco; Maite Pérez; Carlos Rubio-Terrés
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

2.  Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.

Authors:  W H van Harten; V P Retèl
Journal:  Ecancermedicalscience       Date:  2016-10-28

3.  Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

Authors:  Melanie A Lindenberg; Valesca P Retèl; Joost H van den Berg; Marnix H Geukes Foppen; John B Haanen; Wim H van Harten
Journal:  J Immunother       Date:  2018 Nov/Dec       Impact factor: 4.456

Review 4.  Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.

Authors:  Maartje W Rohaan; Joost H van den Berg; Pia Kvistborg; John B A G Haanen
Journal:  J Immunother Cancer       Date:  2018-10-03       Impact factor: 13.751
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.